Potential for Treatment Interval Extension in Eyes with nAMD Disease Activity Post Loading Phase in HAWK and HARRIER.
Ramin TadayoniGlenn J JaffeFrank G HolzUrsula Schmidt-ErfurthKanji TakahashiChui Ming Gemmy CheungSeenu M HariprasadKinfemichael GedifRasmus OlsenCatherine BestFranklin IgwePeter K KaiserPublished in: Ophthalmology and therapy (2023)
These findings indicate that, in eyes that still had DA 8 weeks after the final dose of loading phase, brolucizumab-treated eyes had improved fluid resolution and higher potential for treatment interval extension than aflibercept-treated eyes during the first year of treatment.